Skip to main content
EyeGene,Inc logo

EyeGene,Inc — Investor Relations & Filings

Ticker · 185490 ISIN · KR7185490000 KO Professional, scientific and technical activities
Open in API
Filings indexed 314 across all filing types
Latest filing 2023-11-14 Interim / Quarterly Rep…
Country KR South Korea
Listing KO 185490

About EyeGene,Inc

https://eyegene.co.kr/en/

EyeGene, Inc. is a clinical-stage biopharmaceutical company that researches and develops innovative therapeutics, with a primary focus on gene and cell therapy for age-related diseases. The company's pipeline includes EG-Mirotin, a treatment candidate for non-proliferative diabetic retinopathy and dry age-related macular degeneration. EyeGene is also developing preventive vaccines, such as EG-HPV for cervical cancer, utilizing its proprietary EG-Vac adjuvant system to enhance vaccine efficacy. The company is dedicated to creating transformative treatments by advancing biomedical science.

Recent filings

Filing Released Lang Actions
분기보고서 (2023.09)
Interim / Quarterly Report Classification · 100% confidence The document is a 'Quarterly Report' (분기보고서) for the company 'EyeGene Inc.' (아이진 주식회사) covering the period from January 1, 2023, to September 30, 2023. It contains detailed company information, business overview, management discussion, and financial-related disclosures typical of a formal quarterly filing submitted to the Financial Supervisory Service (FSS) and Korea Exchange. Based on the content and structure, it is classified as an Interim/Quarterly Report. 9M 2023
2023-11-14 Korean
투자판단관련주요경영사항(임상시험계획변경승인신청)( mRNA 기반 코로나-19 예방 다가백신 '이지-코브투(EG-COVII)' 호주 임상 제1/2a상 임상시험 변경 승인신청 )
Regulatory Filings Classification · 100% confidence The document is a regulatory filing from a Korean company (EIDGEN) regarding a 'Major Management Matter' (투자판단 관련 주요경영사항), specifically an application for a change in clinical trial plans for a COVID-19 vaccine. This type of disclosure is a standard regulatory requirement for publicly traded companies in Korea to inform shareholders of material developments in R&D and clinical trials. Since it does not fit into specific categories like financial reports, dividends, or board changes, it falls under the general regulatory filing category.
2023-11-13 Korean
투자판단관련주요경영사항(임상시험계획승인신청등결정)(mRNA 기반 코로나-19 예방 다가백신 '이지-코브투(EG-COVII)' 호주 임상 제1/2a상 임상시험 계획 승인)
Regulatory Filings Classification · 100% confidence The document is a regulatory filing from a Korean company (Eutilex/Eyegene) regarding the approval of a clinical trial (Phase 1/2a for a COVID-19 vaccine). It follows the standard format for 'Major Management Matters' (투자판단 관련 주요경영사항) under Korean stock exchange regulations. Since it details a specific regulatory event (clinical trial approval) rather than a general report or a simple announcement of a report, it falls under the 'Regulatory Filings' category as a specific corporate disclosure.
2023-10-24 Korean
투자판단관련주요경영사항(임상시험계획승인신청)(mRNA 기반 코로나-19 예방 다가백신 '이지-코브투(EG-COVII)' 호주 임상 제1/2a상 임상시험 계획)
Regulatory Filings Classification · 100% confidence The document is a regulatory filing from a Korean company (Eutilex/Eyegene) regarding a 'Major Management Matter' (주요경영사항), specifically the application for approval of a clinical trial (Phase 1/2a for a COVID-19 vaccine). This type of disclosure is a standard regulatory announcement for material corporate events in the Korean market. Since it does not fit into specific categories like M&A, dividends, or financial reports, it falls under the general regulatory filing category.
2023-10-10 Korean
투자판단관련주요경영사항(임상시험결과)(심근허혈 및 재관류 손상 치료후보물질'이지-마이오신(EG-Myocin)' 임상2상시험 결과)
Regulatory Filings Classification · 100% confidence The document is a formal regulatory disclosure filed by Eutilex (아이진) regarding the results of a Phase 2 clinical trial for their drug candidate 'EG-Myocin'. It details the trial methodology, primary endpoints, and the specific clinical outcomes. Since this is a direct disclosure of material clinical trial results to a regulatory body (KRX) rather than a mere announcement of a report's availability, it falls under the category of regulatory filings for material business events.
2023-09-22 Korean
주식매수선택권부여에관한신고
Share Issue/Capital Change Classification · 100% confidence The document is a formal regulatory filing titled '주식매수선택권 부여에 관한 신고' (Report on the Granting of Stock Options) submitted to the Financial Services Commission/Korea Exchange. It details the issuance of stock options to specific individuals, including the number of shares, exercise price, and board resolution details. This type of disclosure regarding capital structure changes and equity-based compensation falls under the category of 'Share Issue/Capital Change' (SHA) as it relates to the issuance of new shares upon the exercise of these options.
2023-09-22 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.